Although 4 of these 8 studies were conducted in the approved chemotherapy setting, 3 of the 4 were anemia-prevention studies that allowed inclusion of patients with high baseline Hb levels [20,22,25] and all 4 studies targeted high Hb values (≥12 g/dL) [8,20,22,25]. This evidence concerns the gene GSTM1 and anemia.